Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2024 Earnings Conference Call December 12, 2023 4:30 PM ET Ronnie Morris - CEO Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please note, this conference is being recorded. Ronnie Morris Before I begin, I will remind you that we'll be making forward-looking statements during today's call and that actual results could differ materially from ...

It is management's responsibility to establish and maintain "disclosure controls and procedures" as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly Report. In designing and evaluating our disclosure co ...

Ronnie Morris - CEO David Baron - Baron Capital Ronnie Morris I'll start by pointing out that our prepared comments for today will be relatively brief as we just recently provided our fiscal year-end results and company update six weeks ago. On that call, I provided an update on the accomplishments from fiscal year 2023, along with the longer-term strategic vision for the company. I also highlighted the challenges we encountered such as the overall economic environment, which led to cancellations well in ex ...

revenue recognized during the period. Deferred revenue is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year. Accounts receivable and unbilled services were as follows (in thousands) Note 4. Revenue from Contracts with Customers | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|--------------|--------------|--------|-------| | | | | | | | | | | | | Three July | Months 31, | Ended | ...

In summary, despite this being a more challenging year than we expected, we have robust bookings, a strong platform, a stellar reputation, and a strong team that is poised for the next growth spurt. Some of these challenges we experienced last year will spill over and continue to impact on our results in the first half of this fiscal year, but we are confident that we are poised to emerge with stronger revenue and profitability over the longer term. Now, let me turn the call over to David Miller for a more ...

Now it's more of just making sure that we can get the word out that we're not just a preclinical. We're also clinical CRO and start getting more customers getting to be comfortable with using us. Operator [Operator Instructions] That concludes your Q&A session. I will now hand the conference back to our host for closing remarks. Please go ahead. Ronnie Morris So I wanted to thank everybody for joining our quarterly conference call. Certainly, it was a challenging quarter in terms of the results. But in term ...

Form 10-Q | --- | --- | |----------------------------------------------------------------------------|--------------------------------------------| | (Exact name of registrant as \nDelaware | defined in its charter) \n52-1401755 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | | | | One University Plaza, Suite 307 | 07601 | | Hackensack, New Jersey | (Zip Code) | (Address of principal executive of ices) Not Applicable (Former name, former address ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2023 Earnings Conference Call December 13, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Scott Henry - ROTH Capital Operator Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for you questions and comments after the presentation. It is now my pl ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|----------------- ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|-------------------- ...